<DOC>
	<DOCNO>NCT00189553</DOCNO>
	<brief_summary>This study efficacy safety Caelyx ( pegylated liposomal doxorubicin ) combination carboplatin compare standard treatment paclitaxel carboplatin patient epithelial ovarian cancer late relapse ( &gt; 6 month ) .</brief_summary>
	<brief_title>Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin Patients With Epithelial Ovarian Cancer Late Relapse</brief_title>
	<detailed_description>The main purpose research study find treatment late relapse ovarian fallopian tube primary peritoneal cancer liposomal doxorubicin ( Caelyx ) combine carboplatin control tumor growth least well standard treatment paclitaxel carboplatin . And hop substitute paclitaxel Caelyx combination carboplatin improve tolerance treatment program least efficacy few side effect .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Patients age &gt; 18 Histologically proven diagnosis cancer ovary , fallopian tube extraovarian papillary serous tumor Measurable disease ( Response Evaluation Criteria Solid Tumor [ RECIST ] criterion ) cancer antigen ( CA ) 125 assessable disease ( Gynecologic Cancer Intergroup [ GCIG ] criterion ) histologically proven diagnosis relapse Disease progression &gt; 6 month first second platinumbased line . Patients previously receive taxane derivative . ECOG performance status &lt; 2 Life expectancy least 12 week Adequate bone marrow , renal , hepatic function Ovarian tumor low malignant potential Nonepithelial ovarian mixed epithelial/nonepithelial tumor Previous radiotherapy Prior diagnosis malignancy Bowel obstruction , subocclusive disease , presence symptomatic brain metastasis Preexisting motor sensory neurologic pathology symptom National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) grade &gt; 1 History congestive heart failure ( New York Heart Association [ NYHA ] classification &gt; 2 ) , history myocardial infarction within last 6 month , history atrial ventricular arrhythmia Severe active infection Severe hypersensitivity product contain Cremophor EL and/or compound chemically related paclitaxel , carboplatin Caelyx Fertile woman use adequate contraceptive method Pregnant breast feeding woman</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Extra-ovarian papillary serous tumor</keyword>
	<keyword>Relapse 6 month</keyword>
	<keyword>Previously receive taxane derivative</keyword>
</DOC>